Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA ...
We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive ...
Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
VOR Biopharma's valuation surged after in-licensing telitacicept and securing PIPE financing, but capital structure uncertainty persists. Telitacicept's positive phase 3 data in Sjögren's disease ...
Following these transactions, Reprogrammed Interchange LLC directly holds 34,213,292 shares of Vor Biopharma Inc. common stock. Reid Hoffman may be deemed a beneficial owner of these shares due to his ...
Thursday, Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel ...
Using the 2 Stage Free Cash Flow to Equity, Vor Biopharma fair value estimate is US$0.31 With US$0.32 share price, Vor Biopharma appears to be trading close to its estimated fair value Analyst price ...
Reprogrammed Interchange LLC, a ten percent owner of Vor Biopharma Inc. (NASDAQ:VOR), reported selling 73,676 shares of common stock on October 15 and 16, 2025, for a total value of $2.35 million. The ...
VOR pivoted from cell therapy to in-licensing telitacicept, securing $175M in private placement but at the cost of massive dilution. Telitacicept offers multi-billion market potential if global trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback